pomalidomide has been researched along with piperidines in 4 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (piperidines) | Trials (piperidines) | Recent Studies (post-2010) (piperidines) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 40,235 | 5,221 | 14,545 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orlowski, RZ | 1 |
| Ding, N; Gao, H; Hwang, J; Liu, W; Rao, Y; Song, Y; Sun, Y; Wu, Y; Yang, Y; Zhao, M; Zhao, X | 1 |
| Batchelor, TT; Grommes, C; Nayak, L; Tun, HW | 1 |
| Chen, L; Li, H; Liu, Y; Wang, Q; Wu, C; Yang, K; Zheng, M; Zhou, Y | 1 |
2 review(s) available for pomalidomide and piperidines
| Article | Year |
|---|---|
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat | 2013 |
Introduction of novel agents in the treatment of primary CNS lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape | 2019 |
2 other study(ies) available for pomalidomide and piperidines
| Article | Year |
|---|---|
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; HEK293 Cells; HeLa Cells; Humans; Lymphoma, B-Cell; Mutation; Piperidines; Protein Domains; Proteolysis; Pyrazoles; Pyrimidines; Thalidomide | 2018 |
Novel PROTACs for degradation of SHP2 protein.
Topics: Cell Cycle; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Molecular Structure; Piperidines; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyrimidines; Structure-Activity Relationship; Thalidomide | 2021 |